Overall market sentiment has been down on Panbela Therapeutics Inc (PBLA) stock lately. PBLA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Panbela Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PBLA!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With PBLA Stock Today?
Panbela Therapeutics Inc (PBLA) stock is unchanged 3.04% while the S&P 500 is up 0.04% as of 1:34 PM on Wednesday, Dec 7. PBLA is unmoved $0.00 from the previous closing price of $0.09 on volume of 1,603,645 shares. Over the past year the S&P 500 is lower by -14.13% while PBLA is down -94.86%. PBLA lost -$2.26 per share in the over the last 12 months.
To screen for more stocks like Panbela Therapeutics Inc click here.
More About Panbela Therapeutics Inc
Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications.
Click Here to get the full Stock Report for Panbela Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
